CL2015002725A1 - Compuestos aromáticos sustituidos para el tratamiento de la fibrosis pulmonar, la fibrosis hepática, la fibrosis de la piel y la fibrosis cardíaca - Google Patents

Compuestos aromáticos sustituidos para el tratamiento de la fibrosis pulmonar, la fibrosis hepática, la fibrosis de la piel y la fibrosis cardíaca

Info

Publication number
CL2015002725A1
CL2015002725A1 CL2015002725A CL2015002725A CL2015002725A1 CL 2015002725 A1 CL2015002725 A1 CL 2015002725A1 CL 2015002725 A CL2015002725 A CL 2015002725A CL 2015002725 A CL2015002725 A CL 2015002725A CL 2015002725 A1 CL2015002725 A1 CL 2015002725A1
Authority
CL
Chile
Prior art keywords
fibrosis
skin
treatment
pulmonary
aromatic compounds
Prior art date
Application number
CL2015002725A
Other languages
English (en)
Spanish (es)
Inventor
Boulos Zacharie
Shaun Abbott
Lyne Gagnon
Pierre Laurin
Brigitte Grouix
Lilianne Geerts
François Sarra-Bournet
Martin Leduc
Jean-François Bienvenu
Valérie Perron
Original Assignee
Prometic Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biosciences Inc filed Critical Prometic Biosciences Inc
Publication of CL2015002725A1 publication Critical patent/CL2015002725A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/42Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C07C57/60Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings having unsaturation outside the rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/42Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/52Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/76Unsaturated compounds containing keto groups
    • C07C59/84Unsaturated compounds containing keto groups containing six membered aromatic rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CL2015002725A 2013-03-15 2015-09-15 Compuestos aromáticos sustituidos para el tratamiento de la fibrosis pulmonar, la fibrosis hepática, la fibrosis de la piel y la fibrosis cardíaca CL2015002725A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361798427P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
CL2015002725A1 true CL2015002725A1 (es) 2016-04-15

Family

ID=51535670

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002725A CL2015002725A1 (es) 2013-03-15 2015-09-15 Compuestos aromáticos sustituidos para el tratamiento de la fibrosis pulmonar, la fibrosis hepática, la fibrosis de la piel y la fibrosis cardíaca

Country Status (25)

Country Link
US (3) US9884802B2 (OSRAM)
EP (1) EP2970088B1 (OSRAM)
JP (1) JP6381557B2 (OSRAM)
KR (1) KR102303493B1 (OSRAM)
CN (1) CN105143170B (OSRAM)
AR (1) AR095427A1 (OSRAM)
AU (1) AU2014231649C1 (OSRAM)
BR (1) BR112015023129A2 (OSRAM)
CA (1) CA2905633C (OSRAM)
CL (1) CL2015002725A1 (OSRAM)
DK (1) DK2970088T3 (OSRAM)
EA (1) EA031511B1 (OSRAM)
ES (1) ES2780825T3 (OSRAM)
IL (1) IL241164B (OSRAM)
MX (1) MX375261B (OSRAM)
MY (1) MY194727A (OSRAM)
NZ (1) NZ712745A (OSRAM)
PH (1) PH12015502012A1 (OSRAM)
PL (1) PL2970088T3 (OSRAM)
PT (1) PT2970088T (OSRAM)
SG (1) SG11201507274PA (OSRAM)
TW (2) TWI742541B (OSRAM)
UY (1) UY35401A (OSRAM)
WO (1) WO2014138907A1 (OSRAM)
ZA (1) ZA201507062B (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Pimキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
ME03780B (me) 2013-01-15 2021-04-20 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
TWI742541B (zh) * 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
EA201690458A1 (ru) 2013-08-23 2016-07-29 Инсайт Корпорейшн Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
PT3203999T (pt) * 2014-10-10 2020-04-23 Liminal Biosciences Ltd Compostos aromáticos substituídos e composições farmacêuticas para a prevenção e tratamento da osteoporose
CA2967499C (en) 2014-11-12 2023-01-17 Prometic Biosciences Inc. Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
WO2016181221A1 (en) 2015-05-13 2016-11-17 Dignity Sciences Limited Compositions comprising 15-oxo-epa or 15-oxo-dgla and methods of making and using same
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
US10046007B2 (en) * 2015-06-24 2018-08-14 Prescient Pharma, Llc Compositions and methods for treatment of short telomere disorders
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
AU2018367193A1 (en) * 2017-11-15 2020-07-02 Galapagos Nv Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US20210205253A1 (en) * 2018-05-31 2021-07-08 The Asan Foundation Use Of Stearic Acid For Preventing Or Treating Pulmonary Fibrosis
CN120923343A (zh) 2018-10-11 2025-11-11 巴斯夫股份公司 芳族化合物及其医药用途
EP3890717A4 (en) * 2018-12-05 2022-08-24 Liminal Biosciences Limited USE OF SODIUM 2-(3-PENTYLPHENYL)ACETATE IN THE TREATMENT OF ALSTRÖM SYNDROME
WO2020146887A1 (en) 2019-01-11 2020-07-16 University Of Virginia Patent Foundation Compositions and methods for predicting lung function decline in idiopathic pulmonary fibrosis
WO2020181163A1 (en) * 2019-03-06 2020-09-10 Tobira Therapeutics, Inc. Lipid-based formulation of cenicriviroc
WO2021015218A1 (ja) * 2019-07-24 2021-01-28 国立大学法人九州大学 転写関連因子を標的とする線維化疾患の予防または治療
CN112441916A (zh) * 2019-08-29 2021-03-05 广东药科大学 新型苯乙酸衍生物、其制备方法及其作为药物的用途
JP2024512510A (ja) * 2020-10-06 2024-03-19 ファーマセウティーク・インジェニュー・インコーポレイテッド 置換芳香族化合物及びその医薬組成物
US12053467B2 (en) 2020-12-18 2024-08-06 NovMeta Pharma Co., Ltd. Method of treating fibrosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20012434A1 (it) 2001-11-20 2003-05-20 Dompe Spa Acidi 2-aril-propionici e composizioni farmaceutiche che li contengono
ES2575100T3 (es) * 2009-05-04 2016-06-24 Prometic Pharma Smt Limited Compuestos aromáticos sustituidos y usos farmacéuticos de los mismos
CA2761061A1 (en) 2009-05-04 2010-11-11 Prometic Biosciences Inc. Salts of 3-pentylphenylacetic acid and pharmaceutical uses thereof
EA030038B1 (ru) * 2010-10-27 2018-06-29 Прометик Фарма Смт Лимитед Применение соединений для лечения рака и способ лечения рака
CN102070433B (zh) * 2010-12-27 2013-03-27 桂林师范高等专科学校 芳香基乙酸类衍生物的制备方法
TWI689490B (zh) * 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療纖維化之經取代之芳族化合物及相關方法
TWI742541B (zh) * 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
CA2967499C (en) * 2014-11-12 2023-01-17 Prometic Biosciences Inc. Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration

Also Published As

Publication number Publication date
BR112015023129A2 (pt) 2017-07-18
MX375261B (es) 2025-03-06
US10450258B2 (en) 2019-10-22
UY35401A (es) 2014-10-31
ES2780825T3 (es) 2020-08-27
JP2016510769A (ja) 2016-04-11
AU2014231649B2 (en) 2018-01-04
CA2905633A1 (en) 2014-09-18
IL241164B (en) 2020-11-30
IL241164A0 (en) 2015-11-30
PH12015502012A1 (en) 2016-01-11
CA2905633C (en) 2021-12-28
KR102303493B1 (ko) 2021-09-16
TWI689489B (zh) 2020-04-01
TW202045469A (zh) 2020-12-16
EA031511B1 (ru) 2019-01-31
EP2970088B1 (en) 2020-01-01
MY194727A (en) 2022-12-15
AR095427A1 (es) 2015-10-14
DK2970088T3 (da) 2020-03-30
TWI742541B (zh) 2021-10-11
US20200017432A1 (en) 2020-01-16
EA201591774A1 (ru) 2015-12-30
JP6381557B2 (ja) 2018-08-29
SG11201507274PA (en) 2015-10-29
MX2015012886A (es) 2016-04-04
NZ712745A (en) 2020-06-26
AU2014231649C1 (en) 2018-08-23
PL2970088T3 (pl) 2020-11-02
PT2970088T (pt) 2020-03-27
US11267779B2 (en) 2022-03-08
WO2014138907A1 (en) 2014-09-18
ZA201507062B (en) 2017-04-26
EP2970088A1 (en) 2016-01-20
AU2014231649A1 (en) 2015-10-22
US20160023983A1 (en) 2016-01-28
EP2970088A4 (en) 2016-10-19
CN105143170A (zh) 2015-12-09
TW201441185A (zh) 2014-11-01
HK1220439A1 (en) 2017-05-05
US20180134649A1 (en) 2018-05-17
CN105143170B (zh) 2019-11-08
KR20160040452A (ko) 2016-04-14
US9884802B2 (en) 2018-02-06

Similar Documents

Publication Publication Date Title
CL2015002725A1 (es) Compuestos aromáticos sustituidos para el tratamiento de la fibrosis pulmonar, la fibrosis hepática, la fibrosis de la piel y la fibrosis cardíaca
IL257978B (en) Use of pasteurized akkermansia for treating metabolic disorders
EP3473726B8 (en) Fermentation technique to improve production level of recombinant human collagen
CL2015002535A1 (es) Compuestos aromáticos sustituidos y método relacionado para el tratamiento de la fibrosis
EP3269378A4 (en) Composition for preventing or treating inflammatory diseases, comprising lactic acid bacteria-derived extracellular vesicles as active ingredients
MX2021006581A (es) Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia.
EP3313991A4 (en) Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
BR112013027307A2 (pt) método para tratar uma matriz de tecido; matriz de tecido acelular
ECSP13012978A (es) Inhibidores de glucosilceramida sintasa
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
MX385332B (es) Moduladores de ror-gamma.
MX2021007268A (es) Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas.
MX381313B (es) Derivados de benzimidazol como moduladores de ror-gamma
MX2015009058A (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
EP4299122A3 (en) Compositions and methods for treating skin and mucous membrane diseases
PT3551748T (pt) Células estaminais do mesênquima derivadas de tecido perinatal: método de preparação e suas utilizações
MX388301B (es) Il-23a y tnf-alfa orientados y compuesto y sus usos.
MX2018005348A (es) Composiciones y metodos para transduccion de tumores.
ZA201904522B (en) Heterocyclic inhibitors of mct4
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
EA201692292A1 (ru) Соединения и композиции для стимулирования хондрогенеза
CL2016000436A1 (es) Método para el tratamiento de la enfermedad fibrótica
MX2015003701A (es) Composiciones para tratamiento.
MX2014005398A (es) Metodos para tratar ataques de gota.
EA201592073A1 (ru) Фармацевтические композиции, содержащие коллаген и гиалуронат натрия